🔗 Share this article

While the US proceeds with historic revisions to its vaccine schedules, a particular individual has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who first made her name by expressing skepticism about Covid shots throughout the pandemic and has zeroed in on alleged deaths after COVID-19 vaccination in her brief position at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Childhood Vaccine Program

Agency leaders were set to reveal radical revisions to the pediatric immunization program earlier this month, aligning the US with the Danish national calendar, it is understood – a major change that would place the US out of alignment with many the international standard with little proof for benefit. This reveal has been postponed until the next year.

Rather than the top vaccines chief, Dr. Høeg is set to speak at the gathering. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the office this year.

A New Direction at the Regulatory Body

The acting appointment may indicate a closer partnership between the drug and biologics divisions as Dr. Høeg and Prasad solidify control at the agency – and it points to a greater focus upon reevaluating already-approved vaccines at the FDA.

The new acting director has repeatedly called for discontinuing certain pediatric vaccine recommendations in the US so as to align more in line with Denmark, a society with nationalized medicine and a population approximately the size of the state of Wisconsin.

So far public appearances, she has continued to focus on immunizations – traditionally the responsibility of Dr. Prasad, director of the FDA’s vaccine center – rather than medication approval.

Doubts Over Background

Dr. Høeg has no obvious experience in drug development, oversight or management, which has been customary for previous heads of the CBER. She has served at the FDA as a key advisor to the commissioner and CBER since spring.

“It seems she lacks to have the necessary background” for overseeing the pharmaceutical oversight division, said Jonathan Howard. “She lacks experience running a scientific study. She is not versed in running a large organization. She is not an expert in pharmaceutical oversight.”

Former heads of the center would “be deeply familiar with legal statutes and the science of medication creation”, commented Janet Woodcock. “Objectively, she lacks the type of experience that former directors who ran the center have had.”

The drug center has an enormous portfolio at the agency, the former commissioner pointed out.

“Many people just zeroes in on the new drug program, but the generic program clears a multitude of generic drugs. There’s a biosimilars program, non-prescription drug unit and so forth, and every single one have to be managed,” she explained. “The area you neglect, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a significant leadership component to the position, which manages over 5,000 staff members. “It’s a massive leadership role, if you execute it properly,” the former official said.

Response and Disputed Initiatives

In response to concerns about Høeg’s credentials and whether this assignment represents more teamwork among regulatory chiefs on vaccines, a press secretary stated that the “concerns stem from flawed assumptions”.

“Her resume matches the responsibilities of her job,” the spokesperson said, pointing to the period Høeg spent guiding the agency head on “pharmaceutical safety and approval science, including computerized risk analysis and shot safety tracking”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s recently launched expedited review system, a controversial one-day medication authorization process that apparently worried her preceding directors. “By what process are these medications being picked for this voucher program? Who is making the calls?” Dr. Howard said. “There’s a lot of secrecy happening at the regulatory body right now.”

In general, he stated, “the Food and Drug Administration seems to be moving towards laxer oversight of pharmaceuticals, aside from vaccines.”

Established History on Vaccines

With vaccines, Dr. Høeg has a clearer, if troubling, past, Howard said. She published a research paper using unverified public submissions to determine the frequency of myocarditis following COVID-19 immunization. She advised the state of Florida top health official Joseph Ladapo, who allegedly have changed statistics to suggest COVID-19 vaccines are pose a greater threat than they are.

Among her “desired changes” for the incoming government encompassed revising rules for novel immunizations and discontinuing “unnecessary” vaccines, she stated post-election on a online show. At the agency, Dr. Høeg has reportedly proposed barring adolescent males from obtaining Covid vaccines.

“She’s an all-around true believer who commences with her preconceived notions and tailors the evidence to fit the evidence in a extremely misleading, dishonest manner,” Howard stated.

Consolidating Power and a “Push for Payback”

Høeg aligned with other dissenters, {like|